Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data - Archive ouverte HAL
Article Dans Une Revue Supportive Care in Cancer Année : 2024

Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data

Olivia Rohr
  • Fonction : Auteur
Sonia Priou
Gilles Chatellier
  • Fonction : Auteur
Samy Babai
  • Fonction : Auteur
Sébastien Gallien
  • Fonction : Auteur
Rémi Flicoteaux
  • Fonction : Auteur
Christophe Tournigand
  • Fonction : Auteur
Emmanuelle Kempf
  • Fonction : Auteur

Résumé

Purpose We aimed at identifying prevalence, clinical outcomes and prognostic factors in cancer patients with intravenous chemotherapy-induced severe neutropenia (ICISN). Methods In this multicenter retrospective cohort study on the clinical data warehouse of Greater Paris University Hospitals (AP-HP), we included all adult patients with solid cancer hospitalized between 2016 and 2021 with intravenous chemotherapy within 30 days prior to severe neutropenia (D70 or D611 ICD-10 codes AND a neutrophil count < 500/mm3). The primary endpoint was referral to intensive care unit (ICU) or death within 30 days. We collected cancer, patient, and treatment characteristics. Results Among 141,586 cancer inpatients, 40,660 received chemotherapy among whom 661 (1.6%) had ICISN. Median age was 63 years (interquartile range (IQR), 54–70) and 330 patients (49%) were female. The median Charlson score was 10 (IQR, 8–11). Main primary cancers were lung (n = 204, 31%) and breast (n = 87, 13%). Advanced cancers were found in 551 patients (83%), 331 (50%) were in 1st line of chemotherapy, 284 (42%) in the 1st cycle of the current line and 149 (22%) had primary G-CSF. Documented bacterial (mostly gram-negative bacilli) and fungal infections were observed in 113 (17%) and 19 (3%) patients; 58 (9%) were transferred to ICU and 82 (12%) died within 30 days, 372 (56%) patients received subsequent chemotherapy. Independent prognostic factors were the level of monocyte, lymphocyte counts or albuminemia and a documented bacterial infection, while Charlson index and primary prophylactic G-CSF were not associated with patient clinical outcomes. Conclusion Despite the use of primary G-CSF, ICISN remains a frequent event, which leads to ICU death in one on five cases Some prognostic factors of severity have been highlighted and could help clinicians to prevent severe complications.
Fichier non déposé

Dates et versions

hal-04697901 , version 1 (14-09-2024)

Identifiants

Citer

Olivia Rohr, Sonia Priou, Gilles Chatellier, Samy Babai, Sébastien Gallien, et al.. Prevalence and risks of intravenous chemotherapy-induced severe neutropenia in solid cancers: a multicenter retrospective cohort study on real-life data. Supportive Care in Cancer, 2024, 32 (10), pp.657. ⟨10.1007/s00520-024-08817-4⟩. ⟨hal-04697901⟩
82 Consultations
0 Téléchargements

Altmetric

Partager

More